Recombinant GDF8 (Lintuzumab Biosimilar) antibody
Quick Overview for Recombinant GDF8 (Lintuzumab Biosimilar) antibody (ABIN7543069)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purpose
- Anti-CD33 [SGN-33 (Lintuzumab)], Rabbit IgG, kappa
-
Specificity
- This antibody is specific for human CD33, which is restricted to cells of the myelomonocytic lineage. CD33 but does not appear in abundance on normal cells, but is over-expressed in AML and other myeloproliferative diseases.
-
Characteristics
-
Original Species of Ab: Human
Original Format of Ab: IgG1
-
Purification
- Protein A affinity purified
-
Immunogen
- This humanized antibody was prepared by combining the CDR regions of the murine anti-CD33 M195 with human framework and constant regions.
-
Isotype
- IgG kappa
-
-
-
-
Application Notes
- In vitro, this antibody is capable of mediating ADCC against AML cells (Caron, 1998). Though shown to be safe in phase III trials, the use of this antibody in combination with induction chemotherapy did not result in a statistically significant improvement in response rate or survival in patients with refractory/relapsed AML (Feldman, 2005).
-
Comment
-
NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 1 mg/mL
-
Buffer
- PBS with 0.02 % Proclin 300.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
-
- GDF8 (Lintuzumab Biosimilar)
-
Alternative Name
- CD33 (Lintuzumab Biosimilar)
-
Target Type
- Biosimilar
-
Background
- Sialic acid-binding Ig-like lectin 3, gp67, HuM195
-
UniProt
- P20138
Target
-